The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Novel insights into the B-cell receptor in high-grade B-cell lymphoma
Stefano Casola, MD, PhD, Institute of Molecular Oncology Foundation, Milan, Italy, provides insight into his work on the origins of high-grade B-cell lymphoma with MYC and BCL2 rearrangements, highlighting the loss of B-cell receptor expression in these tumors and the identification of a putative tumor precursor cell in the preceding follicular lymphoma. Dr Casola explains that his team found a rare fraction of cells in follicular lymphoma that express recombinase genes and are believed to be precursor cells that can evolve into highly malignant tumors, and notes that understanding the biology of these cells can inform treatment strategies, including alternative treatments for patients who may not respond to B-cell receptor-targeting therapies. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
